An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Cited by (336)

Items 101–200 of 336

1. Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes?
   Brooke D. Paradise, Whitney Jo Barham, Martín E. Fernández-Zapico · 2018 · Cancers
2. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase
   Sharan K. Bagal, Clare L. Gregson, Daniel H. O’Donovan, Kurt G. Pike, Andrew Bloecher, Peter Barton, Alexandra Borodovsky, Erin L. Code, Shaun M. Fillery, Jessie Hao-Ru Hsu et al. · 2021 · Journal of Medicinal Chemistry
3. Polycomb-group proteins in the initiation and progression of cancer
   Xiujuan Zhao, Xudong Wu · 2021 · Journal of genetics and genomics/Journal of Genetics and Genomics
4. Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy
   Kwang‐Su Park, Lihuai Qin, Md Kabir, Kaixiu Luo, Brandon Dale, Yue Zhong, Arum Kim, Gang Greg Wang, H. Ümit Kanıskan, Jian Jun Jin · 2023 · Advanced Science
5. Expanding the ligand spaces for E3 ligases for the design of protein degraders
   Rahman Shah Zaib Saleem, Martin P. Schwalm, Stefan Knapp · 2024 · Bioorganic & Medicinal Chemistry
6. SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding
   Michael L. Curtin, Marina A. Pliushchev, Huan‐Qiu Li, Maricel Torrent, Justin D. Dietrich, Clarissa G. Jakob, Haizhong Zhu, Hongyu Zhao, Ying Wang, Zhiqin Ji et al. · 2017 · Bioorganic & Medicinal Chemistry Letters
7. Dysregulated Transcriptional Control in Prostate Cancer
   Simon J. Baumgart, Ekaterina Nevedomskaya, Bernard Haendler · 2019 · International Journal of Molecular Sciences
8. Two Functional Axes of Feedback-Enforced PRC2 Recruitment in Mouse Embryonic Stem Cells
   Matteo Perino, Guido van Mierlo, Chet Hong Loh, Sandra M.T. Wardle, Dick W. Zijlmans, Hendrik Marks, Gert Jan C. Veenstra · 2020 · Stem Cell Reports
9. T herapeutic targeting of chromatin: status and opportunities
   Marton I. Siklos, Stefan Kubicek · 2021 · FEBS Journal
10. The Complex Role of EZH2 in the Tumor Microenvironment: Opportunities and Challenges for Immunotherapy Combinations
    Jing Qiu, Shikhar Sharma, Robert A. Rollins, Thomas A. Paul · 2020 · Future Medicinal Chemistry
11. The application of ubiquitin ligases in the PROTAC drug design
    Yilin Chen, Jianping Jin · 2020 · Acta Biochimica et Biophysica Sinica
12. Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine
    Isabelle A. Engelberg, Caroline A. Foley, Lindsey Ingerman James, Stephen V. Frye · 2021 · Current Opinion in Chemical Biology
13. Chemical biology and pharmacology of histone lysine methylation inhibitors
    Samir H. Barghout, Raquel A. C. Machado, Dalia Baršytė-Lovejoy · 2022 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
14. PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer
    Juyeong Hong, Ji Hoon Lee, Zhao Zhang, Yanming Wu, Mei Yang, Yiji Liao, Richard de la Rosa, Jessica L. Scheirer, Douglas Pechacek, Nu Zhang et al. · 2022 · Cancer Research
15. Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors
    Cinzia Lanzi, Noemi Arrighetti, Sandro Pasquali, Giuliana Cassinelli · 2023 · Biochemical Pharmacology
16. Nucleation and spreading maintain Polycomb domains every cell cycle
    Giovana M. B. Veronezi, Srinivas Ramachandran · 2024 · Cell Reports
17. Recent Structural Insights into Polycomb Repressive Complex 2 Regulation and Substrate Binding
    Vignesh Kasinath, Simon Poepsel, Eva Nogales · 2018 · Biochemistry
18. Reprogramming CBX8-PRC1 function with a positive allosteric modulator
    Junghyun L. Suh, Daniel Bsteh, Bryce Hart, Yibo Si, Tyler Weaver, Carina Pribitzer, Roy Lau, Shivani Soni, Heather Anne N. Ogana, Justin M. Rectenwald et al. · 2021 · Cell chemical biology
19. An overview of the development of EED inhibitors to disable the PRC2 function
    Kailu Liu, Kongkai Zhu, Hua Zhang · 2021 · RSC Medicinal Chemistry
20. Epigenetic controls of Sonic hedgehog guarantee fidelity of epithelial adult stem cells trajectory in regeneration
    Fanyuan Yu, Feifei Li, Liwei Zheng, Ling Ye · 2022 · Science Advances
21. AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
    Kaili Zhang, Qianqian Shen, Yanfen Fang, Yi-ming Sun, Jian Ding, Yi Chen · 2019 · Acta Pharmacologica Sinica
22. Targeting Epigenetic protein–protein Interactions With small-molecule Inhibitors
    Brian M. Linhares, Jolanta E. Grembecka, Tomasz Cierpicki · 2020 · Future Medicinal Chemistry
23. Nucleation and Propagation of Heterochromatin by the Histone Methyltransferase PRC2: Geometric Constraints and Impact of the Regulatory Subunit JARID2
    Eva J. Ge, Krupa S. Jani, Katharine L. Diehl, Manuel M. Müller, Tom W. Muir · 2019 · Journal of the American Chemical Society
24. Chemical inhibitors targeting histone methylation readers
    Xiaolei Huang, Yichang Chen, Qin Xiao, Xinci Shang, Yanli Liu · 2024 · Pharmacology & Therapeutics
25. A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins
    2024
26. Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities
    Rajita J. Vatapalli, Alex P. Rossi, Ho Man Chan, Jingwen Zhang · 2024 · Epigenomics
27. Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal
    Anne‐Marie W. Turner, Raghuvar Dronamraju, Frances Potjewyd, Katherine Sholtis James, Daniel Winecoff, Jennifer Kirchherr, Nancie M. Archin, Edward P. Browne, Brian D. Strahl, David M. Margolis et al. · 2020 · ACS Infectious Diseases
28. Structural heterogeneity of the mammalian polycomb repressor complex in immune regulation
    Seok Jin Kang, Taehoon Chun · 2020 · Experimental & Molecular Medicine
29. Clinical significance and biological function of WD repeat domain 54 as an oncogene in colorectal cancer
    Yuncang Yuan, Guoxiang Qi, Hao Shen, Aizhen Guo, Fuao Cao, Yan Zhu, Chunjie Xiao, Wenjun Chang, Shangyong Zheng · 2018 · International Journal of Cancer
30. Disrupting the Code: Epigenetic Dysregulation of Lymphocyte Function during Infectious Disease and Lymphoma Development
    Andrea Di Pietro, Kim L. Good‐Jacobson · 2018 · The Journal of Immunology
31. Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function
    Hongyu Zhang, Jianping Lu, Yun Jiao, Qi Chen, Min Li, Zichen Wang, Zhendong Yu, Xiaodong Huang, Athena Yao, Qiong Gao et al. · 2019 · Frontiers in Oncology
32. Polycomb group proteins in cancer: multifaceted functions and strategies for modulation
    S P Wang, Sandra Carolina Ordonez‐Rubiano, Alisha Dhiman, Guanming Jiao, Brayden P. Strohmier, Casey J. Krusemark, Emily C. Dykhuizen · 2021 · NAR Cancer
33. The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?
    Yi You, Zhong Chen, Weiwei Hu · 2024 · Pharmacology & Therapeutics
34. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics
    Qichao Bao, Anil Kumar V, Daqing Wu, Jia Zhou · 2024 · Drug Discovery Today
35. Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure
    Jingyi Ding, Yanxi Liu, Yu Lai · 2021 · Frontiers in Immunology
36. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer
    Francesca De Santis, Sandra Lorena Romero-Cordoba, Lorenzo Castagnoli, Tatiana Volpari, Simona Faraci, Giovanni Fucà, Elda Tagliabue, Filippo de Braud, Serenella Maria Pupa, Massimo Di Nicola · 2022 · Cellular Oncology
37. First-in-Class Allosteric Inhibitors of DNMT3A Disrupt Protein–Protein Interactions and Induce Acute Myeloid Leukemia Cell Differentiation
    Jonathan E. Sandoval, Raghav Ramabadran, Nathaniel J. Stillson, Letitia Sarah, Danica Galonić Fujimori, Margaret A. Goodell, Norbert O. Reich · 2022 · Journal of Medicinal Chemistry
38. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
    Daniela Tomaselli, Nicola Mautone, Antonello Mai, Dante Rotili · 2020 · European Journal of Medicinal Chemistry
39. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies
    Satoshi Kaito, Atsushi Iwama · 2020 · International Journal of Molecular Sciences
40. Systematic Variation of Both the Aromatic Cage and Dialkyllysine via GCE-SAR Reveal Mechanistic Insights in CBX5 Reader Protein Binding
    K.M. Kean, Stefanie A. Baril, Kelsey N. Lamb, Sarah N. Dishman, Joseph W. Treacy, Kendall N. Houk, Eric M. Brustad, Lindsey Ingerman James, Marcey L. Waters · 2022 · Journal of Medicinal Chemistry
41. Focus on the classical and non-classical functions of EZH2: Guide the development of inhibitors and degraders
    Qiangsheng Zhang, Hongling Yang, Qiang Feng, Jiaying Cao, Yiqian Zhang, Lu Li, Luoting Yu · 2022 · Pharmacological Research
42. Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain – A fragment based approach
    Anup K. Upadhyay, Russell A. Judge, Leiming Li, Ron B. Pithawalla, Justin A. Simanis, Pierre M. Bodelle, Violeta L. Marin, Rodger F. Henry, Andrew M. Petros, Chaohong C. Sun · 2018 · Bioorganic & Medicinal Chemistry Letters
43. Novel therapeutic strategies for MLL-rearranged leukemias
    Nok-Hei Mickey Wong, Chi Wai Eric So · 2020 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
44. A novel cardiomyogenic role for Isl1 + neural crest cells in the inflow tract
    Konstantinos E. Hatzistergos, Michael A. Durante, Krystalenia Valasaki, Amarylis Claudine Bonito Azeredo Wanschel, J. William Harbour, Joshua M. Hare · 2020 · Science Advances
45. Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma
    Hui Si Kwok, Allyson M. Freedy, Allison P. Siegenfeld, Julia W. Morriss, Amanda L. Waterbury, Stephen M. Kissler, Brian B. Liau · 2023 · Nature Chemical Biology
46. Polycomb and Trithorax Group Proteins: The Long Road from Mutations in Drosophila to Use in Medicine
    Darya Chetverina, Д. В. Ломаев, Maksim Erokhin · 2020 · Acta Naturae
47. Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase
    Daniel H. O’Donovan, Clare L. Gregson, Martin J. Packer, Ryan D. R. Greenwood, Kurt G. Pike, Sameer P. Kawatkar, Andrew Bloecher, James D. Robinson, Jon A. Read, Erin L. Code et al. · 2021 · Bioorganic & Medicinal Chemistry Letters
48. Critical Roles of Polycomb Repressive Complexes in Transcription and Cancer
    Guanjun Dong, Jiale Xu, Yu-Ruo Qi, Ziqiao Yuan, Wen He Zhao · 2022 · International Journal of Molecular Sciences
49. Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED–H3K27me3 Inhibitors for the Treatment of Lymphoma
    Guanjun Dong, Jia-Hui Zuo, Junlin Yu, Jiale Xu, Ge Gao, Guo‐Bo Li, Wen He Zhao, Bin Yu · 2022 · Journal of Medicinal Chemistry
50. PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors
    Jiaqi Zhao, Hui Qian, Yang An, Liping Chu, Dongxia Tan, Chenyang Qin, Qianying Sun, Yunpeng Wang, Wei Qi · 2024 · Journal of Biological Chemistry
51. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs
    Yuan Zhao, Yuanyuan Guan, Fang Zhao, Tong Yu, Shaojie Zhang, Yizhe Zhang, Ying‐Chao Duan, Xiaoli Zhou · 2022 · European Journal of Medicinal Chemistry
52. A plant‐derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy
    Yixuan Wang, Jian Gao, Ying Fang Yu, Lin Zhou, Miao Wang, Wenwen Xue, Бо Лю, Xudong Wu, Xuefeng Wu, Huiyuan Gao et al. · 2022 · British Journal of Pharmacology
53. Nutrigenomic regulation of sensory plasticity
    Hayeon Sung, Anoumid Vaziri, Daniel Wilinski, Riley K.R. Woerner, Peter L. Freddolino, Monica Dus · 2023 · eLife
54. Novel insights of EZH2-mediated epigenetic modifications in degenerative musculoskeletal diseases
    Zetao Ma, Lei Chen, Yushun Wang, Sheng Zhang, Jianrui Zheng, Yuhong Luo, Chao Wang, Hui Zeng, Lixiang Xue, Zhen Wei Tan et al. · 2023 · Ageing Research Reviews
55. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED–EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations
    Kongkai Zhu, Daohai Du, Rui Juan Yang, Hongrui Tao, Hua Zhang · 2019 · Chemical and Pharmaceutical Bulletin
56. Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity
    Jacob I. Stuckey, Nico R. Cantone, Alexandre Côté, Shilpi Arora, Valérie Vivat, Ashwin Ramakrishnan, Jennifer A. Mertz, Avinash Khanna, Jehrod B. Brenneman, Victor S. Gehling et al. · 2021 · Journal of Biological Chemistry
57. Gestational diabetes mellitus causes genome hyper-methylation of oocyte via increased EZH2
    Hongyan Guo, Shoubin Tang, Lijun Li, Jing Lin, Tingting Zhang, Shuo Chao, Xiao-Wen Jin, Kuipeng Xu, Xiaofeng Su, Shen Yin et al. · 2025 · Nature Communications
58. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance
    Liping Chu, Dongxia Tan, Meimei Zhu, Yu-Xiu Qu, Xin Ma, Bao‐Liang Song, Wei Qi · 2023 · Journal of Biological Chemistry
59. Recent progress on small molecules targeting epigenetic complexes
    Yukihiro Itoh, Yuri Takada, Yasunobu Yamashita, Takayoshi Suzuki · 2022 · Current Opinion in Chemical Biology
60. Merkel Cell Carcinoma Sensitivity to EZH2 Inhibition Is Mediated by SIX1 Derepression
    Ashley K. Gartin, Thomas C. Frost, Camille H. Cushman, Brittaney A. Leeper, Prafulla C. Gokhale, James A. DeCaprio · 2022 · Journal of Investigative Dermatology
61. Chromatin-Remodeled State in Lymphoma
    Yuxuan Liu, Yulissa Gonzalez, Jennifer Effie Amengual · 2019 · Current Hematologic Malignancy Reports
62. Activation of Steroidogenesis, Anti-Apoptotic Activity, and Proliferation in Porcine Granulosa Cells by RUNX1 Is Negatively Regulated by H3K27me3 Transcriptional Repression
    Yuyi Zhong, Liying Li, Yingting He, Bo He, Zhonghui Li, Zhe Zhang, Hao Zhang, Xiaolong Yuan, Jiaqi Li · 2020 · Genes
63. Discovery of a novel 53BP1 inhibitor through AlphaScreen-based high-throughput screening
    Yanli Sun, Haibo Lu, Xueyu Fang, Sen-Hao Xiao, Feng Yang, Yantao Chen, Hongbo Wang, Xiaopeng Li, Jing Lu, Hua Lin et al. · 2021 · Bioorganic & Medicinal Chemistry
64. A defined glycosylation regulatory network modulates total glycome dynamics during pluripotency state transition
    Federico Pecori, Ikuko Yokota, Hisatoshi Hanamatsu, Taichi Miura, Chika Ogura, Hayato Ota, Jun‐ichi Furukawa, Shinya Oki, Kazuo Yamamoto, Osamu Yoshie et al. · 2021 · Scientific Reports
65. Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities
    Michał Woźniak, Małgorzata Czyż · 2025 · Therapeutic Advances in Medical Oncology
66. Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma
    Sungryul Park, Seung-Hyun Jo, Jong-Hwan Kim, Seon‐Young Kim, Jae Du Ha, Jong Yeon Hwang, Myeong Youl Lee, Jong Soon Kang, Tae-Su Han, Sung Goo Park et al. · 2020 · Cancers
67. MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells
    Faezeh Tolue Ghasaban, Mahmoud Ghanei, R. A. Mahmoudian, Negin Taghehchian, M. Abbaszadegan, M. Moghbeli · 2024 · Heliyon
68. A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
    Vincent Ribrag, L. Iglesias, Filippo de Braud, Brigette B.Y. Ma, Tomoya Yokota, Thomas Zander, Anna Spreafico, Vivek Subbiah, Anna Lena Illert, Daniel Tan et al. · 2024 · European Journal of Cancer
69. Total synthesis, structural revision and biological evaluation of γ-elemene-type sesquiterpenes
    Changchun Yuan, Shangyong Zhong, Xingyi Li, Yanhong Wang, Miao‐Miao Xun, Yunli Bai, Kongkai Zhu · 2018 · Organic & Biomolecular Chemistry
70. A Solid‐Phase Approach to Accessing Bisthioether‐Stapled Peptides Resulting in a Potent Inhibitor of PRC2 Catalytic Activity
    Gan Zhang, Flavia Barragán, Khadija Wilson, Nissim Levy, Adam Herskovits, Milana Sapozhnikov, Yoel Rodrı́guez, Leutrim Kelmendi, Haleem Alkasimi, Hunter W. Korsmo et al. · 2018 · Angewandte Chemie International Edition
71. Discovery of selective activators of PRC2 mutant EED-I363M
    Junghyun L. Suh, Kimberly D. Barnash, Tigran M. Abramyan, Fengling Li, Juliana The, Isabelle A. Engelberg, Masoud Vedadi, Peter J. Brown, Dmitri Kireev, C.H. Arrowsmith et al. · 2019 · Scientific Reports
72. Inhibition of polycomb repressive complex 2 by targeting EED protects against cisplatin‐induced acute kidney injury
    Chao Yu, Tingting Li, Jialu Li, Binbin Cui, Na Liu, George P Bayliss, Shougang Zhuang · 2022 · Journal of Cellular and Molecular Medicine
73. Know when to fold ‘em: Polycomb complexes in oncogenic 3D genome regulation
    Emma J. Doyle, Lluís Morey, Eric Conway · 2022 · Frontiers in Cell and Developmental Biology
74. Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets
    Lulu Liu, Xin Guo, Yao Wang, Guo Li, Yanyan Yu, Yang Song, Chenhui Zeng, Zhilou Ding, Yuanjun Qiu, Feifei Yan et al. · 2022 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
75. Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancer
    Lianghua Luo, Zhonghao Wang, Tengcheng Hu, Zongfeng Feng, Qingwen Zeng, Xufeng Shu, Ahao Wu, Pan Huang, Yi Cao, Yi Tu et al. · 2022 · Bioscience Reports
76. [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].
    Hao Gong, Yuan Yin, Li Y, Hongbing Zhang, Ying Li, Weiting Li, Pan Wang, Ruifeng Shi, Chao Liu, Liyuan Cui et al. · 2019 · PubMed Central
77. Transcriptome-Wide Identification of Coding and Noncoding RNA-Binding Proteins Defines the Comprehensive RNA Interactome of Leishmania mexicana
    Karunakaran Kalesh, Wenbin Wei, Brian S. Mantilla, Theodoros I. Roumeliotis, Jyoti Sharma Choudhary, Paul William Denny · 2022 · Microbiology Spectrum
78. Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program
    Ying Wang, Rohinton P. Edalji, Sanjay C. Panchal, Chaohong C. Sun, Stevan W. Djurić, Anil Vasudevan · 2017 · Journal of Medicinal Chemistry
79. Binding Modes of Small‐Molecule Inhibitors to the EED Pocket of PRC2
    Dading Huang, Shuaizhen Tian, Yifei Qi, John Z. H. Zhang · 2019 · ChemPhysChem
80. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader
    Md Kabir, Lihuai Qin, Kaixiu Luo, Yan Xiong, Rebecca A. Sidi, Kwang‐Su Park, Jian Jun Jin · 2024 · Journal of Medicinal Chemistry
81. Activation of automethylated PRC2 by dimerization on chromatin
    Paul Victor Sauer, Egor A. Pavlenko, Trinity Cookis, Linda C. Zirden, Juliane Renn, Ankush Singhal, Pascal Hunold, Michaela Nicole Hoehne, Olivia van Ray, Farnusch Kaschani et al. · 2024 · Molecular Cell
82. TRACE generates fluorescent human reporter cell lines to characterize epigenetic pathways
    Iva A. Tchasovnikarova, Sharon K. Marr, Manashree Damle, Robert E. Kingston · 2021 · Molecular Cell
83. Epigenetic silencing of E‐cadherin gene induced by lncRNA MALAT ‐1 in acute myeloid leukaemia
    Jinlong Huang, Jingping Fang, Qinchang Chen, Jinyuan Chen, Jianzhen Shen · 2022 · Journal of Clinical Laboratory Analysis
84. Targeting the polycomb repressive complex-2 related proteins with novel combinational strategies for nasopharyngeal carcinoma.
    Junyu Zhu, Lili Li, JOANNA H.M. TONG, Connie W. C. Hui, Chi Hang Wong, Kwok Wai Lo, Raymond Ngai Chiu Chan, Qi Yong H. Ai, Edwin Pun Hui, Anthony T.�C. Chan et al. · 2020 · PubMed Central
85. The transcriptional elongation factor CTR9 demarcates PRC2-mediated H3K27me3 domains by altering PRC2 subtype equilibrium
    Ngai Ting Chan, Junfeng Huang, Gui Ma, Hao Zeng, Kristine Donahue, Yidan Wang, Lingjun Li, Wei Xu · 2022 · Nucleic Acids Research
86. An update on allosteric modulators as a promising strategy targeting histone methyltransferase
    Zehui Tan, Tong Li, Hongrui Lei, Xin Zhai · 2021 · Pharmacological Research
87. Selective Methyl Labeling of Proteins: Enabling Structural and Mechanistic Studies As Well As Drug Discovery Applications by Solution-State NMR
    Andrew Proudfoot, Andreas O. Frank, Alexandra Frommlet, Andreas Lingel · 2018 · Methods in enzymology on CD-ROM/Methods in enzymology
88. Pharmacological Modulation of Transcriptional Coregulators in Cancer
    Timothy R. Bishop, Yuxiang Zhang, Michael A. Erb · 2019 · Trends in Pharmacological Sciences
89. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED)
    Chao‐Yie Yang, Shaomeng Wang · 2017 · Journal of Medicinal Chemistry
90. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer
    Nikhil Chandnani, Ishika Gupta, Vidhi Thakkar, Koustav Sarkar · 2023 · Pathology - Research and Practice
91. Survivin prevents the polycomb repressor complex 2 from methylating histone 3 lysine 27
    Maja Jensen, Venkataragavan Chandrasekaran, María-José García-Bonete, Shuxiang Li, Atsarina Larasati Anindya, Karin Andersson, Malin C. Erlandsson, N. Yu. Oparina, Björn M. Burmann, Ulrika Brath et al. · 2023 · iScience
92. Domain cross-talk in regulation of histone modifications: Molecular mechanisms and targeting opportunities
    James E. Longbotham, Meng Yao Zhang, Danica Galonić Fujimori · 2020 · Current Opinion in Chemical Biology
93. Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment
    Ji Yue Zhang, Jiang-Wei Zhang, Michael Kiffe, Markus Walles, Yi Jin, Joachim Blanz, Jérôme Dayer, Arévalo Sánchez, Chunye Zhang, Lijun Zhang et al. · 2021 · Xenobiotica
94. Epigenetic regulation of cancer stem cells: Shedding light on the refractory/relapsed cancers
    Libo Xu, Jinghua Zhang, Jicheng Sun, Kunlin Hou, Chenxin Yang, Ying Guo, Xiaorui Liu, Dhan V. Kalvakolanu, Ling Zhang, Baofeng Guo · 2022 · Biochemical Pharmacology
95. Epigenome profiling identifies H3K27me3 regulation of extracellular matrix composition in human corticogenesis
    Nora Ditzer, Ezgi Senoglu, Annika Kolodziejczyk, Theresa M. Schütze, Aikaterina Nikolaidi, Karolin Küster, Katrin Sameith, Sevina Dietz, Răzvan Petru Derihaci, Cahit Birdir et al. · 2025 · Neuron
96. Inhibition of EED activity enhances cell survival of female germline stem cell and improves the oocytes production during oogenesis in vitro
    Jiapeng Wang, Junxian Fang, Mingqian Feng, Liping Li, Lixin Ma, Xiaorong Zhao, Yanfeng Dai · 2023 · Open Biology
97. A Structural Perspective on Gene Repression by Polycomb Repressive Complex 2
    Xin Liu · 2020 · Sub-cellular biochemistry/Subcellular biochemistry
98. Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation
    Mengxue Zhang, Jing Li, Qingwei Wang, Go Urabe, Runze Tang, Yitao Huang, José Verdezoto Mosquera, K. Craig Kent, Bowen Wang, Clint L. Miller et al. · 2023 · Molecular Therapy — Nucleic Acids
99. ELK1-Induced upregulation of long non-coding TNK2-AS1 promotes the progression of acute myeloid leukemia by EZH2-mediated epigenetic silencing of CELF2
    Dongfang Guo, Zhang Ai-rong, Meifang Suo, Ping Wang, Yile Liang · 2022 · Cell Cycle
100. Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models
     Xin Li, Yanhua Chen, Lijuan Bai, Rui Zhao, Yifei Wu, Zhong‐Ru Xie, Jason M. Wu, Nathan J. Bowen, Alira Danaher, Nicholas Cook et al. · 2023 · British Journal of Cancer